

BioLizard announces Swiss subsidiary and service offering for AI-powered digital transformation of life sciences at Biopôle in Lausanne

- New office in a melting pot of innovation: BioLizard enters the Swiss market, taking residence amongst established big pharma companies and ambitious biotech start-ups
- Switzerland is a beacon for biotech, housing headquarters of 20% of European biotech companies and R&D investments reaching a record level of CHF 2.7 B in 2022
- BioLizard uses its AI and data science expertise to enable data-driven drug discovery and development, and R&D processes for biotech, pharma and diagnostics companies

Lausanne (Switzerland) and Ghent (Belgium), January 23, 2024 – BioLizard, the bioinformatics, data analytics and data management service and consulting company heading digital transformation in the life sciences industry, today announced the incorporation of BioLizard SA and the opening of new offices at Biopôle in Lausanne, home to one of the largest biotech hubs in Switzerland. With its new foothold, BioLizard continues its international expansion, driving commercial activities, while deepening its service commitment to Swiss partners and clients.

Liesbeth Ceelen, PhD, CEO of BioLizard, said: "With our new subsidiary we will increase our reach and service power within Switzerland, by meeting the need for expertise and tools for digital transformation of biotech companies – including for Al-enabled, user-friendly software and data infrastructure – at Biopôle and across canton borders. Our employees – the 'Lizards' – are experts in bioinformatics, Al, data analytics and architecture as well as software development. By working closely with clients to create tailor-made solutions and enable the best data-driven decisions, we leverage the unique knowledge of our team to support the therapeutics, diagnostics, animal health and food & agriculture industries. Biopôle houses 120 companies and provides great conditions for us to engage with the Swiss biotech industry and offer our services exactly where our clients need them, and gain access to highly qualified personnel."

"Switzerland plays a leading role in driving global healthcare innovation, with 20% of European biotech companies headquartered in Switzerland and R&D investments reaching a record level of CHF 2.7 billion in 2022", added Yves Muyssen, COO of BioLizard. "Biopôle fosters innovation by combining a number of diverse life sciences companies, ranging from small to large, preclinical to clinical, and research to service. We know from our clients that IT- and AI-based data solutions have become of paramount importance to drive research forward by accelerating speed, decreasing risk and improving quality of results. With this new subsidiary, we look forward to supporting new and existing partners and thereby contributing to the Swiss biotech landscape."

BioLizard offers support to its Swiss clients in strategic consulting, disease profiling, and drug discovery & development from early stages to clinical trials. The company has recently released its BioVerse software platform constituting three applications, for scientific literature searches, microbiome analysis and multi-omics data analysis. The opening of the Swiss office marks the third country BioLizard has expanded to, next to the US and the Netherlands, and their roots in Belgium. Establishing its regional presence, the company will be available for meetings at the Sachs European Life Sciences CEO Forum on February 28 and 29 and the Swiss Biotech Days from April 22 to 23, 2024.



About BioLizard

BioLizard is a leading multi-national bioinformatics, data analytics and data management service and consulting company heading digital transformation in the life sciences industry. Headquartered in Ghent, Belgium, BioLizard is the trusted go-to partner for data strategy and execution with companies across the range from drug discovery to clinical research and diagnostics as well as animal health and food & agriculture. BioLizard accommodates a uniquely qualified team of 50+ experts, "The Lizards", who bring together their expertise and abilities covering data management, software engineering, bioinformatics, advanced data analytics, and Al. Their joint backgrounds in biology and computer sciences enables them to apply specialist understanding to each client's data environment, to provide insights and tools that are aligned with the client's goals and maximize R&D return on investment. With the proprietary BioVerse platform BioLizard takes the next step in providing bespoke software solutions by tailoring its established programs towards specific client needs. For further information, please visit https://lizard.bio/ and follow us on LinkedIn.

About BioVerse

The BioVerse platform is built to meet the growing needs for bespoke software solutions to maximize the potential of the vast amount of research data generated by biotech and pharma companies. Uniquely, it offers a simple interface for scientists, with or without IT background, enabling effective data exploration and interpretation following data analytics in a tailored environment. All BioVerse applications are compatible with each other, and the platform ensures that data is findable, accessible, interoperable and reusable (FAIR), in line with data management best-practices. The platform is designed to be fully extendable and customizable, to ensure operability in any data environment.

BioVerse currently constitutes three applications:

- BioReflect provides at-a-glance and up-to-date global overviews of publications to support unbiased literature searches
- ProBiome applies state-of-the art data analytics to microbiome analysis
- BioMx leverages Al & bioinformatics to efficiently integrate and analyze multi-omics datasets, facilitating next generation target and biomarker discovery.

Contact

BioLizard nv

Liesbeth Ceelen, PhD Phone: +32 470 77 87 22

E-mail: contact@lizard.bio

Media Inquiries

MC Services AG

Eva Bauer

Phone: +49 (0)89 2102280

E-mail: <u>biolizard@mc-services.eu</u>